Business Context and Reporting Period
This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on November 14, 2016. The filing addresses a regulatory compliance issue regarding the company's listing status on the Nasdaq Stock Market and includes a business and commercial update.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on regulatory compliance rather than financial performance data.
Material Changes and Events
- Nasdaq Non-Compliance: The company received a notice from the Nasdaq Listing Qualifications Department stating it is not in compliance with Marketplace Rule 5250(c)(1) due to the failure to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2016.
- Compliance Timeline: Nasdaq rules permit the company to submit a plan to regain compliance by January 13, 2017 (60 calendar days). Upon review, Nasdaq staff may grant an exception extending the compliance period up to 180 calendar days, or until May 8, 2017.
- Company Plan: Supernus anticipates regaining compliance by filing the delinquent Quarterly Report prior to January 13, 2017, or by submitting a formal plan to Nasdaq.
Guidance, Outlook, and Risks
The filing references a press release issued on November 14, 2016, providing a business and commercial update, but the specific content of that update is not detailed in the text of this Form 8-K. The primary risk identified is the potential delisting or failure to satisfy continued listing standards if the company fails to regain compliance with Nasdaq filing requirements within the allotted timeframe.
Investor Verification Checklist
- Verify the status of the Form 10-Q for the quarter ended September 30, 2016, and confirm if it has been filed.
- Monitor whether the company submits a formal compliance plan to Nasdaq by the January 13, 2017 deadline.
- Review the attached press releases (Exhibits 99.1 and 99.2) for details on the business and commercial update mentioned in Item 8.01.
- Check for any subsequent communications from Nasdaq regarding the approval or rejection of the company's compliance plan.